SIRT3 and acute myeloid leukemia: De‐regulation of SIRT3 due to the abnormality of its post‐translational modification may have a significant impact on sensitivity of AML cells to chemotherapies through, at least in part, modulation of mitochondrial ROS production via metabolic enzymes.